Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference

  Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth
                                  Conference

PR Newswire

CHESTERBROOK, Pa., Aug. 8, 2013

CHESTERBROOK, Pa., Aug. 8, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc.
(Nasdaq: AUXL) today announced that executive management will participate in
the Canaccord Genuity Growth Conference to be held August 14-15, 2013 at the
Intercontinental Boston Hotel. Mr. Adrian Adams, Chief Executive Officer and
President, is scheduled to present an overview of the Company and its product
pipeline at 3:30 p.m. ET on Thursday, August 15, 2013. 

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

The presentation will also be webcast on the "For Investors" section of the
Auxilium website under the "Events" tab on August 15, 2013. To access the
live webcast, please log on to Auxilium's website approximately fifteen
minutes prior to the presentation to register and download any necessary audio
software. The presentation replay will be available for ninety days after the
event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium
histolyticum (CCH)) for the treatment of adult Dupuytren's contracture
patients with a palpable cord in the U.S. Ferring International Center S.A.
markets Testim in certain countries of the EU and Paladin Labs Inc. markets
Testim in Canada. Swedish Orphan Biovitrium AB has marketing rights for
XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 71
Eurasian and African countries. Asahi Kasei Pharma Corporation has
development and commercial rights for XIAFLEX in Japan and Actelion
Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada, Australia, Brazil and Mexico. Auxilium also markets TESTOPEL®, a
long-acting implantable testosterone replacement therapy, Edex®, the leading
branded non-oral drug for erectile dysfunction, Striant®, a buccal system for
testosterone delivery, Osbon ErecAid®, the leading device for aiding erectile
dysfunction, and also has a non-promoted respiratory franchise, including
Theo-24® and Semprex®-D, along with three other non-promoted products, in the
U.S. Auxilium has three projects in clinical development. XIAFLEX is in
phase III of development for the treatment of Peyronie's disease. CCH is in
phase II of development for the treatment of Frozen Shoulder syndrome
(adhesive capsulitis) and phase II of development for the treatment of
cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights
to pursue additional indications for XIAFLEX. For additional information,
visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995

This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, which discuss matters that
are not facts, and may include words to indicate their uncertain nature such
as "believe," "expect," anticipate," "intend," "plan," "could," "estimate,"
"project," "will," and "target." Our forward-looking statements convey
management's expectations, beliefs, plans and objectives regarding future
performance of the Company and are based upon preliminary information and
management assumptions. No specific assurances can be given with respect to
whether: Company management will present at the Canaccord Genuity Growth
Conference; or the Company will be successful in obtaining FDA approval for
its product candidates. While the Company may elect to update the
forward-looking statements made in this news release in the future, the
Company specifically disclaims any obligation to do so. Such forward-looking
statements are subject to a wide range of risks and uncertainties that could
cause results to differ in material respects, including those relating to
product development, revenue, expense and earnings expectations, intellectual
property rights, results and timing of clinical trials, success of marketing
efforts, the need for additional research and testing, and the timing and
content of decisions made by regulatory authorities, including the U.S. Food
and Drug Administration, and those risks discussed in our reports on file with
the Securities and Exchange Commission (the "SEC"). Our SEC filings may be
accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of the Company's home page on the Internet at
http://www.auxilium.com under the heading "For Investors - SEC Filings."
There may be additional risks that the Company does not presently know or that
the Company currently believes are immaterial which could also cause actual
results to differ from those contained in the forward-looking statements.

AUXILIUM CONTACTS:
James E. Fickenscher / CFO       Nichol Ochsner/ Senior Director,
                                            IR
Auxilium Pharmaceuticals, Inc.      Auxilium Pharmaceuticals, Inc.
(484) 321-5900  (484) 321-5900
jfickenscher@auxilium.com        nochsner@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com
 
Press spacebar to pause and continue. Press esc to stop.